Accuray Incorporated (NASDAQ:ARAY) COO Kelly Londy sold 99,136 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Accuray Incorporated (NASDAQ ARAY) traded up 3.49% during midday trading on Friday, reaching $4.45. 423,312 shares of the company’s stock traded hands. Accuray Incorporated has a 52 week low of $3.60 and a 52 week high of $6.05. The stock’s market capitalization is $370.15 million. The company’s 50-day moving average price is $4.19 and its 200 day moving average price is $4.37.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Accuray had a negative net margin of 7.71% and a negative return on equity of 61.62%. The business had revenue of $112.09 million for the quarter, compared to the consensus estimate of $112.00 million. During the same period in the previous year, the business posted ($0.09) EPS. Accuray’s revenue was up 18.0% compared to the same quarter last year. On average, equities research analysts expect that Accuray Incorporated will post ($0.20) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Accuray Incorporated (ARAY) COO Sells 99,136 Shares of Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/insider-selling-accuray-incorporated-aray-coo-sells-99136-shares-of-stock.html.

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in shares of Accuray by 116.3% in the first quarter. Goldman Sachs Group Inc. now owns 30,173 shares of the medical equipment provider’s stock valued at $143,000 after purchasing an additional 16,223 shares during the period. Bank of Nova Scotia bought a new position in shares of Accuray in the second quarter valued at approximately $168,000. AHL Partners LLP raised its position in shares of Accuray by 28.4% in the second quarter. AHL Partners LLP now owns 39,823 shares of the medical equipment provider’s stock valued at $189,000 after purchasing an additional 8,817 shares during the period. PEAK6 Investments L.P. bought a new position in shares of Accuray in the first quarter valued at approximately $193,000. Finally, UBS Asset Management Americas Inc. raised its position in shares of Accuray by 253.5% in the second quarter. UBS Asset Management Americas Inc. now owns 41,697 shares of the medical equipment provider’s stock valued at $198,000 after purchasing an additional 29,900 shares during the period. 76.67% of the stock is currently owned by institutional investors.

ARAY has been the subject of several research analyst reports. Jefferies Group LLC dropped their price target on shares of Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Zacks Investment Research raised shares of Accuray from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. BTIG Research reiterated a “hold” rating on shares of Accuray in a research note on Thursday, August 24th. Royal Bank Of Canada reiterated a “hold” rating and set a $5.00 price objective on shares of Accuray in a research note on Thursday, August 24th. Finally, BidaskClub downgraded shares of Accuray from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $6.00.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Receive News & Stock Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related stocks with our FREE daily email newsletter.